Background
Tuberculosis (TB) is one of the most common infectious disease in the world and the leading cause of death from a single infectious agent. TB is caused by
Mycobacterium tuberculosis, a bacterium which attacks the lungs predominantly but can affect other organs as well. According to a 2018 WHO report, there were approximately 10.0 million people acquiring TB in 2017. Further, TB caused an estimated 1.3 million deaths in 2017. In addition to the high rate of TB incidence, a growing concern is the prevalence of drug-resistant TB. In 2017, 558,000 new TB patients exhibited resistance to the first-line drug rifampicin, more than 80% of which demonstrated eventual multidrug-resistant TB [
1]. Thus, TB remains a significant public health problem requiring effective interventions.
With the development of next-generation high-throughput sequencing, the investigation of the human gut microbiome has become more feasible and has led to insights into gut microbiota. Gut microbiota are a complex and dynamic ecosystem harbouring more than 100 trillion commensal microorganisms, surpassing the number of human cells [
2]. A great amount of evidence suggests that the gut microbiota exerts many beneficial effects on humans through the involvement physiological processes including digestion and absorption of nutrition, modulation of the immune system, and protection against pathogenic invasion [
3‐
7]. Increasing lines of evidence have further indicated that the gut microbiota are linked to some systemic infectious diseases [
8‐
10] such as HIV infection, chronic hepatitis C and bloodstream infection. In addition, the critical role of gut microbiota in pulmonary infectious disease has also been increasingly recognized and a vital cross-talk mechanism between the gut and lung (termed the “gut-lung axis”) has been previously proposed [
11,
12]. The gut-lung axis is bidirectional and its interactions include two aspects: on the one hand, some respiratory diseases including asthma and influenza are strongly linked to a dysbiotic gut microbiota [
13,
14]. On the other hand, a protective role of the gut microbiota against invasion of the lung by pathogenic microorganisms may be achieved by modulation of the local and systemic immunity of the host [
7,
15,
16].
Although gut microbiota may impact the etiology of pulmonary diseases, there have been few explorations to-date focusing on the characterization of gut microbiota in TB patients, especially in pediatric groups which represent a clinically important population with increased susceptibility to TB [
17]. Thus, the present study was developed to explore the gut microbiota of children diagnosed with pulmonary tuberculosis (PTB).
Discussion
The present study is the first to characterize the gut microbiota in pediatric PTB patients through the amplification of next-generation sequencing technology. The results of this study demonstrated that the patterns of gut microbiota in PTB patients were significantly different from healthy controls. The dysbiosis of gut microbiota in PTB patients was specifically characterized by an up-regulation of the pro-inflammatory bacteria Prevotella and the opportunistic pathogen Enterococcus. Further, a reduction of the beneficial bacteria Ruminococcaceae, Bifidobacteriaceae and prausnitzii was observed. This study also revealed that after one-month of effective anti-tuberculosis therapy, the richness of fecal microbiota is similarly decreased.
It is evident that the richness and diversity of gut microbiota plays a critical role in maintaining the health of the human body and that decreases in the richness and diversity of gut microbiota has been linked to diseases including influenza, asthma and HIV infection [
13,
20,
21]. The results of this study indicated that the diversity of gut microbiota in PTB patients is generally decreased, which was demonstrated by the descending Simpson index value. This was not surprising given that some animal experiments have revealed similar findings [
22,
23]. Winglee
et. al. reported that mice infected with aerosolized
Mycobacterium tuberculosis presented a rapid decrease in fecal microbiotal diversity [
22]. In addition, Namasivayam
et. al. found that compared with healthy controls, the diversity of gut microbiota in a murine model of TB presented a slight but significant reduction 12 weeks after infection [
23]. In contrast, the results of Luo
et. al. demonstrated that both new and recurrent TB patients maintained an increased richness of gut microbiota when compared with healthy subjects, and there were no significant differences in the Shannon and Simpson indices of fecal microbiotal diversity [
24]. The discrepancies between that study and the present study may be due to differences in the subjects recruited. In the study by Luo
et. al., the participants were adults, some of which had previously received antibiotic treatment (prior to admission). However, the present study was focused specifically on the pediatric population. Additionally, none of the enrolled participants including the PTB group nor healthy controls had received antibiotics of any kind one month prior to hospital admission. We speculate that in either humans or mice, when infected with PTB, the local immunity of the lung is not singularly affected, rather the immune status of the intestine can be modulated due to crosstalk via the gut-lung axis. Thus, the altered immunity of the intestinal mucosa may contribute to a reduction of diversity in gut microbiota.
In the present study, although the total community of gut microbiota in patients with PTB and healthy controls presented no obvious differences, the relative abundance of some special bacteria at the family, genus and species levels were markedly different between the two groups. These results reflected a significant overrepresentation of
Prevotella in PTB patients when compared with healthy controls. Previously, the increased abundance of
Prevotella at mucosal sites has been reportedly involved with the development of many inflammatory diseases through the stimulation of the local and systemic immune response [
25]. Similarly, Mutlu
et. al. and Ling
et. al. have reported that the relative abundance of
Prevotella was predominant in HIV patients’ intestines when compared with healthy controls [
26,
27]. Interestingly, a prospective exploration performed by Luo
et. al. reported that the levels of
Prevotella are positively correlated with the number of peripheral CD 4
+ cells in new tuberculosis patients. They hypothesized that
Prevotella may regulate the immune status of the host and therefore may be related to the prognosis and outcome of TB patients [
24]. However, the exact mechanism of
Prevotella’s role in the development of PTB in children remains unclear. Based on the findings of this study, we hypothesize that the increased abundance of
Prevotella may activate pulmonary and systematic inflammatory reactions within the host to aggravate TB. This may be achieved through the regulation of the intestinal mucosa immunity and the subsequent increased production of pro-inflammatory cytokines, though this remains to be substantiated in a pediatric population.
Enterococcus is an opportunistic pathogen which usually inhabits the alimentary tract of humans and is associated with many infectious disease including urinary tract infections, surgical wound infections, and bacteraemia [
28]. In this study, PTB patients demonstrated a significant abundance of
Enterococcaceae and
Enterococcus in comparison with the healthy controls. The research performed by Krisna
et. al. presented a similar result, in that
Enterococcus was more predominant in the TB sputum samples than healthy subjects [
29]. Additionally, Sabino
et. al. reported that the microbiota of patients with primary sclerosing cholangitis was characterized by an abundance of
Enterococcus and that genus was associated with disease severity [
30]. On the one hand, the predominance of
Enterococcus in PTB patients was hypothesized to be associated with an impaired epithelial barrier and intestinal permeability, resulting in bacterial translocation from the intestinal tract into systemic circulation where an immune inflammatory reaction could be triggered, thus contributing to the development of tuberculosis. On the other hand, it is worth highlighting that some pathogens are species-specific. Thus, accurate identification of specific pathogen species presents a future direction of study.
Interestingly, the structural imbalance of gut microbiota in patients with PTB is not only coupled with significant overrepresentation of pro-inflammatory bacteria and opportunistic pathogens, but also the significant depletion of beneficial bacteria. In the present study, F.
ruminococcaceae and F.
prausnitzii, belonging to the genus
Faecalibacterium, were significant lower in the PTB group than in healthy controls. Previous studies have described that F.
ruminococcaceae and F.
prausnitzii may exert beneficial effects on human health though their metabolites, short-chain fatty acids (SCFA) [
31,
32]. SCFAs are able to affect lipid, glucose, and cholesterol metabolism in many tissues, where a large proportion are used as a source of energy [
33]. SCFAs can also regulate the proliferation of colonic epithelial cells and enhance the permeability of the intestinal mucosa [
34]. SCFAs, especially butyrate, seem to exert a profound impact on the maintenance of immune homeostasis through broad anti-inflammatory effects, such as the regulation, migration, and adhesion of immune cells, the expression of inflammatory cytokines, and inhibition of histone deacetylases. Cellular proliferation, activation and apoptosis via a host of other signalling pathways have also been implicated in the scope of SCFA’s effects [
35]. Besides the significant depletion of butyrate-producing bacteria, another beneficial bacterium,
Bifidobacteriaceae, was also found to be reduced in PTB group. As a common bacterium in the human gastrointestinal tract,
Bifidobacterium (which belongs to the family
Bifidobacteriaceae) exerts a lot of beneficial effects on the host [
36,
37]. Some studies have reported that reductions of
Bifidobacterium has been associated with many diseases, such as influenza, asthma and cystic fibrosis [
13,
14,
38]. We hypothesize that the depletion of these beneficial bacteria promotes the development of the PTB through many pathways, including but not limited to reducing the immune response against the invasion of foreign microbes and inducing the dysbiosis of systematic inflammatory regulation.
The present study also elucidated a significant reduction of the richness of gut microbiota in PTB patients after one-month of anti-tuberculosis treatment. This finding is supported by research performed by Namasivayam
et. al [
23], which achieved similar results in mice after anti-tuberculosis treatment, wherein the richness of gut microbiota of the mice was similarly decreased. However, the relative abundance of gut microbiota between the patients upon admission and after one-month of treatment presented no significant difference in our study, which was in contrast to the results of Namasivayam
et. al [
23]. Namasivayam
et. al. reported that the relative abundance of the gut microbiota in TB mice before and after anti-tuberculosis treatment were significantly different. Several factors may account for this discrepancy. One obvious difference would be the species of the subject population. While Namasivayam
et. al. utilized an animal model of TB, the present study evaluated human children with TB. Another possibility is that the anti-tuberculosis treatment regimen was different between the two studies. In our study, all patients received a 4-drug regimen including isoniazid, rifampicin, pyrazinamide and ethambutol. But in the study of Namasivayam
et, all mice received a 3-drug regimen including isoniazid, rifampin, and pyrazinamide. We speculated that changes in the gut microbiota of PTB patients after treatment may be linked to the following factors. First, the direct effect of the anti-tuberculosis drugs on the gut microbiota. Second, the bidirectionality of gut-lung interactions could be such that when the immunity of the pulmonary condition is improved, the local immunity of intestine (as well as gut microbiota) may be proportionally improved through the influenced of the ‘gut-lung axis’ cross-talk.
There were several limitations in the present study. First, owing to the risk of radiation exposure to healthy children, this study did not obtain chest X-ray to exclude PTB in healthy controls. However, tuberculin test, medical history and a physical examination were used to eliminate the possibility of PTB in healthy controls. It has been reported that the sensitivity and specificity of the tuberculin test for screening TB is greater than 80% [
39], thus it can be reliably used to detect TB in subject pools. The present study was limited by the cross-sectional research design, inhibiting the ability to detect causal relationships between the gut microbiota and the development of PTB. Another limitation is the relative small simple size. Because only 18 patients were enrolled in our study, so we didn’t analyze the characterization of gut microbiota in PTB patients in different age groups including infant, childhood and adolescent groups. What’s more, present study only explored changes in the gut microbiota of six PTB patients after one-month of anti-tuberculosis treatment and therefore may not comprehensively reflect the changes in the gut microbiota of pediatric PTB patients after anti-tuberculosis treatment. Finally, a large-scale, multi-center study would be required to validate this initial characterization of the gut microbiota of pediatric TB patients.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.